GO:0031773 kisspeptin receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0031773 (kisspeptin receptor binding) is a molecular function describing the binding of a ligand to a kisspeptin receptor, the canonical receptor being KISS1R/GPR54.
• Kisspeptin-KISS1R binding is the master switch for GnRH neuron activation and therefore for the hypothalamic-pituitary-gonadal (HPG) axis and puberty onset.
• The interaction is not confined to the brain: kisspeptin receptor binding also operates in the ovary, in osteoclasts and in astrocytes, giving the term broad physiological reach.
• Both agonists and antagonists of kisspeptin receptor binding are actively pursued as pharmacological tools and therapeutic candidates.
• Dysregulated kisspeptin receptor binding is implicated in hypogonadotropic hypogonadism, polycystic ovary syndrome and bone loss.
• CRISPR knockout, point-mutation, knock-in and overexpression models are the standard way to test whether a candidate gene causally participates in kisspeptin receptor binding.
Description
GO:0031773, kisspeptin receptor binding, is a molecular function term in the Gene Ontology that captures the physical interaction between a kisspeptin ligand and a kisspeptin receptor. The best-characterized receptor in this class is KISS1R (also known as GPR54), a G-protein coupled receptor that is activated by the products of the KISS1 gene, including kisspeptin-10, kisspeptin-13, kisspeptin-14 and kisspeptin-54. Because this binding event sits at the top of the reproductive cascade, it has become one of the most intensively studied ligand-receptor interactions in neuroendocrinology. For researchers, GO:0031773 is therefore not an abstract annotation: it defines the molecular step that determines whether GnRH neurons fire, whether puberty proceeds, and whether gonadal steroidogenesis is maintained. The term is also increasingly relevant outside the hypothalamus, since kisspeptin receptor binding has been documented in ovarian tissue, in bone-resorbing osteoclasts and in astrocytes that modulate the reproductive axis. Understanding the precise molecular requirements of this binding event, and the genes that support it, is essential for anyone modelling reproductive disease, designing kisspeptin-based therapeutics, or interpreting single-cell and spatial transcriptomics data from the HPG axis.
kisspeptin receptor binding At A Glance
| GO ID | GO:0031773 |
|---|---|
| GO term | kisspeptin receptor binding |
| Ontology | molecular_function |
| Definition | Binding to a kisspeptin receptor. |
| Synonym | G-protein coupled receptor 54 binding; hOT7T175 receptor binding; hypogonadotropin-1 receptor binding; KiSS-1 receptor binding; kisspeptin receptor ligand; metastin receptor binding |
| Major function | Ligand recognition at KISS1R/GPR54, initiating GnRH neuron activation and HPG axis control |
| Principal ligand | Kisspeptin peptides derived from the KISS1 gene, including kisspeptin-10 and kisspeptin-54 |
| Principal receptor | KISS1R (GPR54), a G-protein coupled receptor |
| Tissue context | Hypothalamus, ovary, osteoclasts, astrocytes |
What Is GO:0031773?
In plain terms, GO:0031773 describes the function of a molecule that binds to a kisspeptin receptor. The QuickGO definition states simply: binding to a kisspeptin receptor. This places the term in the molecular_function aspect of the Gene Ontology, where it is used to annotate gene products that physically contact KISS1R/GPR54 or a related kisspeptin receptor. Synonyms recorded in QuickGO include G-protein coupled receptor 54 binding, hOT7T175 receptor binding, hypogonadotropin-1 receptor binding, KiSS-1 receptor binding, kisspeptin receptor ligand and metastin receptor binding. The term does not describe downstream signalling per se; it describes the recognition event itself, which is the prerequisite for the G-protein-coupled activation that follows.
Why Is kisspeptin receptor binding Important in Cell Biology?
Kisspeptin receptor binding is important because it is the molecular gatekeeper of reproduction. Without productive binding between kisspeptin and KISS1R, GnRH neurons are not adequately stimulated, LH and FSH secretion falls, and the downstream gonadal axis collapses. This single binding event therefore links a small peptide ligand to fertility, puberty timing, bone remodelling and ovarian function. It is also a tractable drug target: both agonists and antagonists of kisspeptin receptor binding have been developed and are being evaluated for reproductive and non-reproductive indications.
• Defines the molecular trigger for GnRH neuron activation and puberty onset.
• Controls LH and FSH release and therefore gonadal steroidogenesis and gametogenesis.
• Operates in the ovary, where kisspeptin/KISS1R signalling influences follicular function.
• Acts in osteoclasts, where kisspeptin-10 binding to Gpr54 prevents bone loss via Dusp18-mediated Src dephosphorylation.
• Functions in astrocytes, where kisspeptin signalling modulates the reproductive axis.
• Is the target of both agonist and antagonist drug discovery programmes.
• Is dysregulated in polycystic ovary syndrome and in hypogonadotropic hypogonadism.
• Provides a clean molecular endpoint for CRISPR knockout and knock-in studies of reproductive genes.
• Underpins interpretation of single-cell and spatial transcriptomics of the hypothalamus and gonads.
• Offers a bridge between neuroendocrinology, bone biology and reproductive medicine.
What Happens During kisspeptin receptor binding?
Ligand availability and processing
In simple terms: First, the kisspeptin peptide has to be made and released where the receptor is.
Kisspeptin receptor binding begins with the production of KISS1-derived peptides. The KISS1 gene encodes a precursor that is proteolytically processed into kisspeptin-54, kisspeptin-14, kisspeptin-13 and the shortest active form, kisspeptin-10, all of which retain the C-terminal RF-amide motif required for receptor recognition. These peptides are released from KISS1-expressing neurons in the hypothalamus and act on KISS1R-expressing GnRH neurons, and they are also produced in peripheral tissues such as the ovary. The availability of ligand is therefore the first determinant of whether GO:0031773 occurs at a given synapse or tissue site.
Receptor recognition and binding at KISS1R
In simple terms: The kisspeptin peptide docks onto the kisspeptin receptor like a key in a lock.
The core of GO:0031773 is the physical docking of kisspeptin to KISS1R/GPR54. KISS1R is a G-protein coupled receptor, and kisspeptin binding engages its transmembrane pocket to stabilize an active conformation. This recognition event is highly specific: the RF-amide C-terminus of kisspeptin is the principal determinant of binding, which is why synthetic agonists and antagonists are designed around this motif. In osteoclasts, the same binding event has been shown to occur between kisspeptin-10 and Gpr54, demonstrating that the molecular function is conserved across cell types.
Downstream signalling initiated by binding
In simple terms: Once the peptide is bound, the receptor switches on signals inside the cell.
Binding of kisspeptin to KISS1R activates G-protein-coupled signalling, which in GnRH neurons leads to depolarization and GnRH release, and in peripheral tissues activates pathways such as AKT. In osteoclasts, kisspeptin-10 binding to Gpr54 recruits Dusp18, which dephosphorylates Src and thereby restrains bone resorption. In astrocytes, kisspeptin signalling modulates the reproductive axis through glial-neuronal communication. These examples show that GO:0031773 is the upstream molecular event that licenses a diverse set of downstream cellular responses.
Integration at the HPG axis level
In simple terms: The binding event is translated into whole-body reproductive control.
At the systems level, kisspeptin receptor binding in the hypothalamus drives the pulsatile release of GnRH, which in turn controls LH and FSH secretion from the pituitary and gonadal steroidogenesis. This is why loss-of-function of KISS1R or KISS1 causes hypogonadotropic hypogonadism, and why the timing of puberty is so sensitive to the strength of this binding interaction. The same axis is perturbed in polycystic ovary syndrome, where kisspeptin-GPR54 signalling and downstream AKT/SHBG pathways are altered.
Pharmacological modulation of the binding event
In simple terms: Drugs can be designed to mimic or block the kisspeptin-receptor handshake.
Because GO:0031773 is a discrete molecular recognition step, it is druggable. Kisspeptin antagonists have been developed to block the interaction and suppress the reproductive axis, while agonists are explored for conditions requiring axis activation. Recent reviews catalogue the strategies used to discover both classes of molecules and their implications for human health and disease. This pharmacological tractability is a direct consequence of the well-defined binding function annotated by GO:0031773.
Key Genes Involved in GO:0031773 kisspeptin receptor binding
The genes and proteins below are the principal players that support, mediate or are regulated by kisspeptin receptor binding.
| Gene | Major Role | Research Relevance |
|---|---|---|
| KISS1 | Encodes the kisspeptin precursor that is processed into active RF-amide peptides | Ligand source for GO:0031773; central to puberty and fertility studies |
| KISS1R (GPR54) | G-protein coupled receptor that binds kisspeptin | The canonical receptor in GO:0031773; loss-of-function causes hypogonadotropic hypogonadism |
| GNRH1 | Encodes GnRH, the downstream neuropeptide released after KISS1R activation | Readout of kisspeptin receptor binding in the hypothalamus |
| GNRHR | Pituitary receptor for GnRH | Links hypothalamic kisspeptin binding to gonadotropin secretion |
| LHB | Luteinizing hormone beta subunit | Peripheral biomarker of HPG axis activation by kisspeptin |
| FSHB | Follicle-stimulating hormone beta subunit | Peripheral biomarker of HPG axis activation by kisspeptin |
| DUSP18 | Phosphatase recruited after kisspeptin-10 binding to Gpr54 in osteoclasts | Mediates dephosphorylation of Src and bone protection |
| SRC | Kinase dephosphorylated downstream of kisspeptin-Gpr54 binding in osteoclasts | Effector of kisspeptin receptor binding in bone |
| AKT1 | Kinase in the kisspeptin-GPR54-AKT pathway | Links receptor binding to metabolic and ovarian signalling |
| SHBG | Sex hormone-binding globulin | Downstream component of the kisspeptin-GPR54-AKT-SHBG system in PCOS |
| GFAP | Astrocyte marker | Identifies astrocytes in which kisspeptin signalling modulates the reproductive axis |
| ESR1 | Estrogen receptor alpha | Mediates steroid feedback onto kisspeptin neurons |
| ESR2 | Estrogen receptor beta | Contributes to gonadal steroid feedback on the HPG axis |
| KISS1R ligands (kisspeptin-10, -13, -14, -54) | Peptide products of KISS1 that bind the receptor | Direct molecular probes for GO:0031773 assays |
| GNAQ | G-protein alpha subunit implicated in KISS1R signalling | Downstream transducer after receptor binding |
| ARRB1 | Beta-arrestin, regulator of GPCR desensitization | Modulates duration of KISS1R signalling after ligand binding |
| POMC | Pro-opiomelanocortin, co-expressed in some hypothalamic circuits | Context for kisspeptin neuron integration |
| LEPR | Leptin receptor, metabolic input to kisspeptin neurons | Links energy status to kisspeptin receptor binding |
How Is kisspeptin receptor binding Regulated?
Kisspeptin receptor binding is regulated at multiple levels. Ligand availability is controlled by KISS1 gene expression and peptide processing, and KISS1 neurons receive steroid feedback through estrogen receptor signalling. At the receptor level, GPCR desensitization and beta-arrestin recruitment modulate the duration of signalling after binding. Metabolic cues, including leptin signalling, influence the activity of kisspeptin neurons and therefore the probability that binding occurs. In peripheral tissues, the consequences of binding are further tuned by phosphatases such as DUSP18 in osteoclasts and by AKT-pathway components in the ovary. Pharmacological agonists and antagonists provide external control over the binding event.
kisspeptin receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| KISS1R | Hypogonadotropic hypogonadism, delayed puberty | Knockout mouse and knock-in human variant models |
| KISS1 | Hypogonadotropic hypogonadism, infertility | Knockout and overexpression cell models |
| GPR54 (KISS1R) in osteoclasts | Bone loss, osteoporosis | Osteoclast-specific knockout and point-mutation models |
| Kisspeptin-GPR54-AKT-SHBG axis | Polycystic ovary syndrome | Rodent PCOS models with pathway modulation |
| Astrocytic kisspeptin signalling | Reproductive axis dysregulation | Astrocyte-specific knockout and tagged knock-in models |
Hypogonadotropic hypogonadism and delayed puberty
Loss-of-function of KISS1R or KISS1 abolishes productive kisspeptin receptor binding and causes hypogonadotropic hypogonadism, a condition characterized by low GnRH, low gonadotropins and absent or delayed puberty. This makes GO:0031773 a direct molecular entry point for diagnosing and modelling reproductive failure.
Polycystic ovary syndrome
In polycystic ovary syndrome, the kisspeptin-GPR54-AKT-SHBG system is dysregulated, and interventions that modulate this pathway can attenuate the phenotype in experimental models. The binding function annotated by GO:0031773 is therefore mechanistically linked to a common endocrine disorder.
Bone loss and osteoclast biology
Kisspeptin-10 binding to Gpr54 in osteoclasts activates Dusp18-mediated dephosphorylation of Src and prevents bone loss, revealing that GO:0031773 has skeletal consequences beyond reproduction. This expands the disease relevance of the term into osteoporosis research.
Reproductive axis modulation by glia
Kisspeptin signalling in astrocytes modulates the reproductive axis, indicating that non-neuronal cells participate in the regulation of this binding function. This has implications for understanding how the HPG axis is tuned in health and disease.
From kisspeptin receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is KISS1R required for GnRH neuron activation? | KISS1R knockout mouse and KO cell lines |
| Does a human KISS1R variant impair ligand binding? | Point-mutation knock-in of the variant |
| Can a tagged receptor be used to visualize binding? | Tagged knock-in of KISS1R |
| Does overexpression of kisspeptin increase downstream signalling? | KISS1 overexpression cell and animal models |
| Does osteoclast Gpr54 mediate bone protection? | Osteoclast-specific Gpr54 knockout |
| Do astrocytes contribute to reproductive control via kisspeptin? | Astrocyte-specific knockout and knock-in models |
How to Study the kisspeptin receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding assay | Direct ligand-receptor interaction and affinity | Characterizing kisspeptin analogues and antagonists |
| CRISPR knockout | Requirement of a gene for binding and downstream function | Testing KISS1R and KISS1 causality |
| Point-mutation knock-in | Effect of a specific variant on binding | Modelling human hypogonadotropic hypogonadism variants |
| Tagged knock-in | Receptor localization and trafficking | Visualizing KISS1R in cells and tissues |
| RNA-seq | Transcriptional response to kisspeptin stimulation | Mapping downstream pathways of receptor binding |
| Phospho-proteomics | Signalling changes such as Src dephosphorylation | Dissecting DUSP18-mediated effects in osteoclasts |
| In vivo hormone profiling | LH, FSH and steroid levels | Assessing HPG axis integrity |
| Astrocyte-specific manipulation | Glial contribution to reproductive control | Studying non-neuronal modulation of the axis |
Ligand-receptor binding assays
Direct binding assays using radiolabelled or fluorescently labelled kisspeptin peptides are the most straightforward way to measure GO:0031773. Competition with unlabelled kisspeptin-10 or with antagonists allows determination of affinity and specificity, and is the standard approach used in kisspeptin antagonist development.
CRISPR-based genetic perturbation
Knockout of KISS1 or KISS1R, or knock-in of patient variants, provides causal evidence that a given gene product is required for kisspeptin receptor binding and its downstream effects. These models are particularly valuable because they distinguish binding function from downstream signalling.
Transcriptomic and signalling readouts
RNA-seq and phospho-proteomics after kisspeptin stimulation reveal the transcriptional and signalling consequences of receptor binding, including AKT pathway activation and DUSP18-mediated Src dephosphorylation. These readouts connect the molecular function to cellular phenotypes.
In vivo reproductive phenotyping
Measurement of LH, FSH, gonadal steroids and puberty timing in genetically modified animals is the gold-standard functional test of whether kisspeptin receptor binding is intact. Such phenotyping is essential for translating molecular findings into reproductive physiology.
How CRISPR Can Be Used to Study GO:0031773 kisspeptin receptor binding
Knockout
CRISPR knockout of KISS1 or KISS1R eliminates the ligand or receptor and therefore abolishes GO:0031773. This is the cleanest way to test whether a candidate gene is required for kisspeptin receptor binding and its physiological consequences, and it has been used in both neuronal and osteoclast contexts.
Point Mutation
Point-mutation knock-in allows precise modelling of human variants that alter the binding interface or the receptor pocket. Such models are essential for distinguishing variants that impair binding from those that impair downstream signalling, and they directly inform genetic diagnosis of hypogonadotropic hypogonadism.
Knock-in
Knock-in of epitope tags or fluorescent reporters into KISS1R enables visualization of the receptor and its binding partners in native tissue. This approach is valuable for mapping where kisspeptin receptor binding occurs and how the receptor traffics after ligand engagement.
Overexpression
Overexpression of KISS1 or KISS1R increases the probability of ligand-receptor encounter and amplifies downstream signalling. This is useful for gain-of-function studies and for sensitizing cell models to detect subtle effects of binding modulators.
How EDITGENE Supports kisspeptin receptor binding Research
Researchers studying kisspeptin receptor binding-related genes often need to determine whether a candidate gene is causally involved in ligand recognition, receptor activation or downstream reproductive physiology. Answering that question requires precise genetic models in which the gene of interest can be removed, mutated, tagged or overexpressed in a controlled background. EDITGENE provides the full toolkit for these experiments, from knockout cell lines to knock-in animals and CRISPR library screens, so that hypotheses about GO:0031773 can be tested with publication-grade rigor.
Contact EDITGENE today to design your custom CRISPR model for kisspeptin receptor binding research.
Frequently Asked Questions About kisspeptin receptor binding
What is GO:0031773?
GO:0031773 is the Gene Ontology molecular function term for kisspeptin receptor binding, defined as binding to a kisspeptin receptor.
What is kisspeptin receptor binding?
It is the physical interaction between a kisspeptin peptide, such as kisspeptin-10, and its receptor, most commonly KISS1R/GPR54.
What genes are involved in kisspeptin receptor binding?
The principal genes are KISS1, which encodes the ligand, and KISS1R (GPR54), which encodes the receptor, with downstream players including GNRH1, DUSP18, SRC and AKT1.
Which receptor does kisspeptin bind to?
Kisspeptin binds primarily to KISS1R, also known as GPR54, a G-protein coupled receptor.
Why is kisspeptin receptor binding important for reproduction?
Because it is the molecular trigger that activates GnRH neurons and thereby controls LH, FSH, puberty and fertility.
Is kisspeptin receptor binding involved in diseases?
Yes; it is implicated in hypogonadotropic hypogonadism, polycystic ovary syndrome and bone loss.
Can kisspeptin receptor binding be blocked pharmacologically?
Yes, kisspeptin antagonists have been developed to block the interaction, and agonists are also under investigation.
How do researchers study kisspeptin receptor binding?
Common methods include radioligand binding assays, CRISPR knockout and knock-in models, RNA-seq, phospho-proteomics and in vivo hormone profiling.
Does kisspeptin receptor binding occur outside the brain?
Yes, it has been documented in the ovary, in osteoclasts and in astrocytes.
What CRISPR models are used to study kisspeptin receptor binding?
Knockout, point-mutation knock-in, tagged knock-in and overexpression models are all used to test causality and mechanism.
Conclusion
GO:0031773, kisspeptin receptor binding, is a compact molecular function with an outsized physiological footprint. It defines the recognition event between KISS1-derived peptides and KISS1R/GPR54, the step that initiates GnRH neuron activation and controls the entire hypothalamic-pituitary-gonadal axis. Beyond reproduction, the same binding function operates in osteoclasts, the ovary and astrocytes, linking it to bone biology, ovarian function and glial control of the reproductive axis. Because the interaction is both mechanistically well defined and pharmacologically tractable, it continues to attract drug discovery efforts aimed at agonists and antagonists. For researchers, the path forward is clear: use precise CRISPR models to test causality, combine binding assays with transcriptomic and proteomic readouts, and interpret findings against the rich clinical literature on reproductive disease.
References
- 1. Xie Q et al.. 2022. The Role of Kisspeptin in the Control of the Hypothalamic-Pituitary-Gonadal Axis and Reproduction.. Front Endocrinol (Lausanne) 13:925206 PMID: 35837314
- 2. Li Z et al.. 2024. Kisspeptin-10 binding to Gpr54 in osteoclasts prevents bone loss by activating Dusp18-mediated dephosphorylation of Src.. Nat Commun 15(1):1300 PMID: 38346942
- 3. Kaprara A et al.. 2018. The hypothalamus-pituitary-gonad axis: Tales of mice and men.. Metabolism 86:3-17 PMID: 29223677
- 4. Hu KL et al.. 2017. Kisspeptin/Kisspeptin Receptor System in the Ovary.. Front Endocrinol (Lausanne) 8:365 PMID: 29354093
- 5. Torres E et al.. 2024. Kisspeptin signaling in astrocytes modulates the reproductive axis.. J Clin Invest 134(15) PMID: 38861336
- 6. Roseweir AK et al.. 2013. Kisspeptin antagonists.. Adv Exp Med Biol 784:159-86 PMID: 23550006
- 7. Hu R et al.. 2024. Jiawei Buzhong Yiqi Decoction attenuates polycystic ovary syndrome through regulating kisspeptin-GPR54-AKT-SHBG system.. Phytomedicine 133:155931 PMID: 39116604
- 8. Chen X et al.. 2025. Kisspeptin Receptor Agonists and Antagonists: Strategies for Discovery and Implications for Human Health and Disease.. Int J Mol Sci 26(10) PMID: 40430029
